United Therapeutics Wins Patent Ruling Against Liquidia, Seeks Yutrepia Withdrawal
UTHR sits 35% above its 52-week low of $409.07 on elevated volume (5.6× avg).
Summary
United Therapeutics won a federal court ruling that Liquidia induces infringement of its inhaled treprostinil patent for PH-ILD. The court rejected Liquidia's invalidity defense, and United Therapeutics is now seeking to force Yutrepia off the market for that indication. This protects Tyvaso and Tyvaso DPI from a key competitor and could add damages and royalties. BTIG upgraded UTHR to Buy with a $728 target, reflecting the strengthened market position. The ruling follows recent FDA acceptances for ralinepag and nebulized Tyvaso, reinforcing the company's pulmonary hypertension franchise.
At the time of this announcement, UTHR was trading at $550.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.2B. The 52-week trading range was $409.07 to $609.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.